Guardant Health Inc. (GH)

Guardant Health basically leads in liquid biopsy oncology diagnostics using genomic and digital technologies for early cancer detection. One of its main offerings is Guardant360, which is currently ge...

On Tuesday, the Centers for Medicare & Medicaid Services (CMS) approved the Advanced Diagnostic Laboratory Test (ADLT) status for Guardant Health, Inc.'s GH Shield blood test for colorectal cancer (CR...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 11, 2025, the Compensation Committee of Guardant's Board ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of the second annual “Closing the Gap: CRC Screening Insights”...

Here is how Guardant Health (GH) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.

On Thursday, Guardant Health GH reported fourth-quarter adjusted EPS loss of 62 cents, compared to a loss of 64 cents a year ago, beating the consensus loss of 74 cents.

Call Start: 16:30 January 1, 0000 5:31 PM ET Guardant Health, Inc. (NASDAQ:GH ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Zarak Khurshid - Vice President, IR H...

The headline numbers for Guardant Health (GH) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street...

Guardant Health (GH) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $1.58 per share a year ago.

Guardant Health (GH -3.26%), a leader in precision oncology testing, announced its fourth-quarter results on Feb. 20. Total revenue rose 30% year over year to $201.8 million, outpacing analysts' conse...